DK0725779T3 - Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner - Google Patents

Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner

Info

Publication number
DK0725779T3
DK0725779T3 DK94931725T DK94931725T DK0725779T3 DK 0725779 T3 DK0725779 T3 DK 0725779T3 DK 94931725 T DK94931725 T DK 94931725T DK 94931725 T DK94931725 T DK 94931725T DK 0725779 T3 DK0725779 T3 DK 0725779T3
Authority
DK
Denmark
Prior art keywords
amino
fluoro
benzopyrans
disubstituted
carbamoyl
Prior art date
Application number
DK94931725T
Other languages
Danish (da)
English (en)
Inventor
John Leslie Evenden
Eva Maria Hammarberg
Hans Sverker Hansson
Sven Erik Hellberg
Lars George Johansson
Johan Rune Michael Lundkvist
Svante Bertil Ross
Daniel Dungan Sohn
Seth Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK0725779T3 publication Critical patent/DK0725779T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK94931725T 1993-10-28 1994-10-26 Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner DK0725779T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/144,671 US5420151A (en) 1989-12-22 1993-10-28 Chroman derivatives
PCT/SE1994/001010 WO1995011891A1 (en) 1993-10-28 1994-10-26 Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes

Publications (1)

Publication Number Publication Date
DK0725779T3 true DK0725779T3 (da) 2001-10-29

Family

ID=22509617

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94931725T DK0725779T3 (da) 1993-10-28 1994-10-26 Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner

Country Status (36)

Country Link
US (9) US5420151A (de)
EP (1) EP0725779B1 (de)
JP (1) JP3089276B2 (de)
CN (1) CN1062269C (de)
AT (1) ATE203019T1 (de)
AU (1) AU687115B2 (de)
BR (1) BR9407910A (de)
CA (1) CA2173257C (de)
CZ (1) CZ284371B6 (de)
DE (1) DE69427704T2 (de)
DK (1) DK0725779T3 (de)
EE (1) EE03253B1 (de)
ES (1) ES2160640T3 (de)
FI (1) FI961809A (de)
GR (1) GR3036816T3 (de)
HK (1) HK1002898A1 (de)
HR (1) HRP940890B1 (de)
HU (1) HUT75060A (de)
IL (1) IL111365A (de)
IS (1) IS1904B (de)
LV (1) LV12811B (de)
MY (1) MY111616A (de)
NO (1) NO314146B1 (de)
NZ (1) NZ275176A (de)
PL (1) PL178840B1 (de)
PT (1) PT725779E (de)
RU (1) RU2142951C1 (de)
SA (1) SA94150317B1 (de)
SG (1) SG52320A1 (de)
SI (1) SI0725779T1 (de)
SK (1) SK280527B6 (de)
TW (1) TW399049B (de)
UA (1) UA44717C2 (de)
WO (1) WO1995011891A1 (de)
YU (1) YU49048B (de)
ZA (1) ZA948353B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
ATE197145T1 (de) * 1991-02-08 2000-11-15 Lilly Co Eli Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane
WO1995013272A1 (fr) * 1993-11-10 1995-05-18 Japan Tobacco Inc. Derive de chromanne et utilisation therapeutique de ce dernier
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
SE9701438D0 (sv) * 1997-04-17 1997-04-17 Astra Ab A new process
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
SE9703378D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
US5962488A (en) 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
IL156595A0 (en) 2001-01-16 2004-01-04 Astrazeneca Ab Therapeutic heterocyclic compounds
US7032572B2 (en) * 2002-06-04 2006-04-25 Ford Global Technologies, Llc Method for controlling an engine to obtain rapid catalyst heating
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US20060205807A1 (en) * 2005-02-16 2006-09-14 Wyeth Amino-chroman compounds and methods for preparing same
US8846742B2 (en) * 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
JP5372771B2 (ja) * 2006-12-12 2013-12-18 ビアル−ポルテア アンド シー．エイ．， エス．エイ． プロセス
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8412336B2 (en) * 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US9320908B2 (en) * 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
EP3490607A4 (de) * 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. Verbindungen und zusammensetzungen und verwendungen davon
MA45857A (fr) 2016-07-29 2021-05-19 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
CA2972203C (en) 2017-06-29 2018-07-17 Exxonmobil Upstream Research Company Chasing solvent for enhanced recovery processes
CA2974712C (en) 2017-07-27 2018-09-25 Imperial Oil Resources Limited Enhanced methods for recovering viscous hydrocarbons from a subterranean formation as a follow-up to thermal recovery processes
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
CA2978157C (en) 2017-08-31 2018-10-16 Exxonmobil Upstream Research Company Thermal recovery methods for recovering viscous hydrocarbons from a subterranean formation
CA2983541C (en) 2017-10-24 2019-01-22 Exxonmobil Upstream Research Company Systems and methods for dynamic liquid level monitoring and control
EP3938045A1 (de) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salze einer isochromanylverbindung und kristalline formen, verfahren zur herstellung, therapeutische verwendungen und pharmazeutische zusammensetzungen davon
US12007369B2 (en) * 2021-04-01 2024-06-11 Saudi Arabian Oil Company Residual corrosion inhibitor monitoring

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795874A (fr) * 1972-02-25 1973-08-23 Glaxo Lab Ltd Procede de preparation d'esters optiquement actifs d'alpha-amino-acides
JPS60152425A (ja) * 1984-01-20 1985-08-10 Oyo Seikagaku Kenkyusho:Kk ラセミ体の新規な光学分割法
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
GR862239B (en) * 1985-09-03 1986-12-31 Ciba Geigy Ag 3-amino-dihydro-(1)-benzopyrans and benzothiopyrans
FR2593504B1 (fr) * 1986-01-30 1988-12-09 Ile De France Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
US5026707A (en) * 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5225596A (en) * 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
IL114715A (en) * 1989-02-27 1997-01-10 Lilly Co Eli Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes
US5306830A (en) * 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
RU2086535C1 (ru) * 1989-05-31 1997-08-10 Дзе Апджон Компани Производные 1,2,3,4-тетрагидро-2-нафтиламина
DE3942418A1 (de) * 1989-12-21 1991-06-27 Guenther Strecker Gestellstab
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
ES2100211T3 (es) * 1990-08-15 1997-06-16 Lilly Co Eli 2-amino-1,2,3,4-tetrahidronaftalenos, 3-aminocromanos y 3-aminotiocromanos sustituidos en el anillo.
HRP920935A2 (en) * 1991-10-08 1995-08-31 Astra Ab New therapeutically active compound

Also Published As

Publication number Publication date
BR9407910A (pt) 1996-11-26
FI961809A (fi) 1996-05-20
CA2173257A1 (en) 1995-05-04
AU8069794A (en) 1995-05-22
CN1062269C (zh) 2001-02-21
IL111365A0 (en) 1994-12-29
NO961687D0 (no) 1996-04-26
MY111616A (en) 2000-09-27
US5500425A (en) 1996-03-19
NO314146B1 (no) 2003-02-03
YU62294A (sh) 1997-07-31
SK280527B6 (sk) 2000-03-13
HRP940890B1 (en) 2001-12-31
DE69427704T2 (de) 2002-05-02
GR3036816T3 (en) 2002-01-31
JPH09504287A (ja) 1997-04-28
SG52320A1 (en) 1998-09-28
WO1995011891A1 (en) 1995-05-04
US5420151A (en) 1995-05-30
IL111365A (en) 2000-12-06
IS4226A (is) 1995-04-29
LV12811B (en) 2002-08-20
US5641807A (en) 1997-06-24
SI0725779T1 (de) 2001-12-31
NZ275176A (en) 1997-11-24
US5646309A (en) 1997-07-08
ES2160640T3 (es) 2001-11-16
ZA948353B (en) 1995-05-02
US5656658A (en) 1997-08-12
EP0725779A1 (de) 1996-08-14
NO961687L (no) 1996-06-03
HRP940890A2 (en) 1996-12-31
US5639784A (en) 1997-06-17
FI961809A0 (fi) 1996-04-26
PT725779E (pt) 2001-12-28
ATE203019T1 (de) 2001-07-15
JP3089276B2 (ja) 2000-09-18
US5650524A (en) 1997-07-22
SK43696A3 (en) 1996-10-02
RU2142951C1 (ru) 1999-12-20
UA44717C2 (uk) 2002-03-15
AU687115B2 (en) 1998-02-19
CA2173257C (en) 2005-12-06
EP0725779B1 (de) 2001-07-11
US5656657A (en) 1997-08-12
LV12811A (en) 2002-04-20
PL314086A1 (en) 1996-08-19
HK1002898A1 (en) 1998-09-25
SA94150317B1 (ar) 2005-10-15
IS1904B (is) 2003-11-20
YU49048B (sh) 2003-07-07
CZ284371B6 (cs) 1998-11-11
PL178840B1 (pl) 2000-06-30
CN1136811A (zh) 1996-11-27
TW399049B (en) 2000-07-21
HUT75060A (en) 1997-03-28
DE69427704D1 (de) 2001-08-16
EE03253B1 (et) 2000-02-15
HU9601103D0 (en) 1996-06-28
US5639772A (en) 1997-06-17
CZ111496A3 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
SE9504661D0 (sv) New compounds
SE9604786D0 (sv) New compounds
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BG100830A (en) Naphthylamides as central nervous system agents
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
YU211087A (en) Process for obtaining new n-substituted benzimidazolic derivatives
SE9802208D0 (sv) Novel compounds
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
SE9802209D0 (sv) Novel compounds
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
SE9504662D0 (sv) New compounds
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması